Cetuximab in addition to oxaliplatin, fluorouracil and radiotherapy for patients with esophageal cancer treated without surgery

Date 29 June 2016
Event ESMO World Congress on Gastrointestinal Cancer 2016
Session ESMO World Congress on Gastrointestinal Cancer 2016 - Abstracts book
Presenter G. Alexandersson von Döbeln
Citation Annals of Oncology (2016) 27 (2): 1-85. 10.1093/annonc/mdw199
Authors G. Alexandersson von Döbeln1, G. Wagenius1, E. Holtved2, O. Hjortland Geir3, M. Nilsson4, L. Baeksgaard5
  • 1Karolinska Institutet, Stockholm, Sweden, /
  • 2Odense University Hospital, Odense, Denmark, /
  • 3Oslo University Hospital, Oslo, Norway, /
  • 4Karolinska Institutet, Huddinge, Sweden, /
  • 5Rigshospitalet, Copenhagen, Denmark, /


This multicenter phase II trial investigated the addition of cetuximab to chemoradiotherapy in patients with esophageal cancer not suitable for surgery. Aims were to evaluate progression-free survival at 1 year, overall survival and toxicity.